Title : Gangliosides as a therapeutic agent in experimental multiple sclerosis
Abstract:
The most common disease of the entire group of myelin diseases is multiple sclerosis (MS). Experimental autoimmune encephalomyelitis (EAE) in rats is an experimental model of human multiple sclerosis. Usually the disease begins at a young age and almost inevitably leads to disability. The pathogenesis is based on the inflammatory process, progressive demyelination and damage to axons. The disease is characterized by the development of numerous sclerotic foci mainly in the white matter of the brain and spinal cord, as well as significant functional impairment.Currently, much attention is paid to the study of the role of nitric oxide (NO), as a universal transmitter, in the development of various pathological conditions. The aim of this work is to study the effect of a ganglioside-containing drug on the properties, biological role, and mechanisms of action of nitric oxide and sulfhydryl groups in experimental autoimmune encephalomyelitis. As a therapeutic agent, we used the drug Cronassial, the structure of which includes mono-di-tri-sialgangliosides. The results of our study show that during EAE there is an increase in the content of nitric oxide, a decrease in the content of reduced sulfhydryl groups with an increase in the amount of oxidized ones. The data obtained indicate the development of oxidative and nitrosative stresses, which contributes to the development of mitochondrial insufficiency. Administration of a ganglioside-containing drug (cronassial) to animals with EAE led to a partial normalization of the studied parameters.
Audience Take Away Notes:
- Gangliosides first used in EAE
- states the antioxidant role ganglioside-containing drug
- regulation of inflammatory processes in the studied pathology
- The work is experimental and it can be assumed that in the future the use of gangliosides will have a positive effect on improving the quality of life of patients with multiple sclerosis
